• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    7/11/24 2:02:49 PM ET
    $AAL
    $ASNS
    $ASTH
    $BDRX
    Air Freight/Delivery Services
    Consumer Discretionary
    Telecommunications Equipment
    Telecommunications
    Get the next $AAL alert in real time by email

    Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates.

    The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro.

    Conagra Brands shares declined 3.9% to $27.70 on Thursday.

    Here are some other stocks moving in today’s mid-day session.

    Gainers

    • Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care for patients with glioblastoma.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares jumped 78.6% to $1.2698 after the company reported 12-month Phase 2 trial results for eRapa in treating Familial Adenomatous Polyposis.
    • Volcon, Inc. (NASDAQ:VLCN) climbed 68.2% to $6.13 in response to a series of buy-sell transactions by UBS Group AG (NYSE:UBS).
    • iSpecimen Inc. (NASDAQ:ISPC) jumped 48% to $0.4241.
    • Renalytix Plc (NASDAQ:RNLX) gained 35% to $0.4125 after the company announced a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease.
    • Blue Star Foods Corp. (NASDAQ:BSFC) shares rose 33.6% to $2.2450 after declining around 5% on Wednesday.
    • Cyngn Inc. (NASDAQ:CYN) gained 32.5% to $5.25. Cyngn announced the expansion of its dealer network to include Alta Equipment Group.
    • Methode Electronics, Inc. (NYSE:MEI) shares rose 29.4% to $12.22 after the company reported better-than-expected fourth-quarter sales results.
    • QuantumScape Corporation (NYSE:QS) gained 25% to $6.76 after the company announced it entered into an agreement with PowerCo to industrialize solid-state batteries.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) jumped 18.2% to $8.63.
    • SoundHound AI, Inc. (NASDAQ:SOUN) rose 16.7% to $5.92. SoundHound AI recently announced that its ChatGPT-integrated voice assistant is now live and in production in Peugeot, Opel and Vauxhall vehicle brands in Europe.
    • LL Flooring Holdings, Inc. (NYSE:LL) jumped 15.4% to $0.7850.
    • Astrana Health, Inc. (NASDAQ:ASTH) gained 11.2% to $42.47. Truist Securities analyst Jailendra Singh upgraded Astrana Health from Hold to Buy and raised the price target from $44 to $50.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) shares rose 10.8% to $7.76.
    • Ribbon Communications Inc. (NASDAQ:RBBN) climbed 10.8% to $3.60 after Rosenblatt initiated coverage on the stock with a Buy rating and announced a $5 price target.
    • OKYO Pharma Limited (NASDAQ:OKYO) gained 10.2% to $1.3003 as the company announced plans to initiate neuropathic corneal pain trial for OK-101.
    • Actelis Networks, Inc. (NASDAQ:ASNS) shares rose 9.7% to $1.72 after the company announced it received a significant order valued at $260,000 to modernize the traffic systems in a major Mid-Atlantic county in the United States.
    • NaaS Technology Inc. (NASDAQ:NAAS) shares gained 8.4% to $5.07 after surging 44% on Wednesday.
    • Lantheus Holdings, Inc. (NASDAQ:LNTH) rose 8.2% to $114.89. Leerink Partners maintained Lantheus with an Outperform and raised the price target from $106 to $127.
    • MicroStrategy Incorporated (NASDAQ:MSTR) rose 8% to $1,410.01 after the company announced a 10-for-1 stock split.
    • Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) rose 7.6% to $1.8307.
    • Pool Corporation (NASDAQ:POOL) gained 6.6% to $318.49.

    Losers

    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) dipped 28.1% to $5.32 after jumping 110% on Wednesday. Inspire Veterinary Partners announced the closing of $6 million public offering.
    • Cingulate Inc. (NASDAQ:CING) fell 25% to $0.4862 after gaining 74% on Wednesday.
    • Crown LNG Holdings Limited (NASDAQ:CGBS) dipped 18.6% to $2.5102.
    • Telesis Bio, Inc. (NASDAQ:TBIO) declined 18.2% to $3.5736.
    • Boqii Holding Limited (NYSE:BQ) dipped 17.6% to $0.4271.
    • TuanChe Limited (NASDAQ:TC) shares fell 17.5% to $1.5996.
    • Clene Inc. (NASDAQ:CLNN) fell 15.7% to $4.7350. Clene announced plans to submit briefing book to the U.S. FDA in connection with granted Type C interaction to obtain FDA feedback on potential pathway to accelerated approval for CNM-Au8 in ALS.
    • E2open Parent Holdings, Inc. (NASDAQ:ETWO) declined 15.7% to $3.72 after the company reported worse-than-expected first-quarter sales results.
    • uniQure N.V. (NASDAQ:QURE) dipped 14.2% to $8.68. The company recently announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of
    • Longeveron Inc. (NASDAQ:LGVN) shares fell 9.4% to $4.1191. Longeveron shares jumped over 58% on Wednesday after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to Lomecel-B for the treatment of mild Alzheimer’s Disease.
    • ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) dipped 9% to $18.06.
    • Innovative Eyewear, Inc. (NASDAQ:LUCY) fell 8% to $0.4210 after gaining over 20% on Wednesday.
    • BRC Inc. (NYSE:BRCC) fell 7.7% to $4.9850.
    • Delta Air Lines, Inc. (NYSE:DAL) fell 7.1% to $43.56 after the company posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook.
    • American Airlines Group Inc. (NASDAQ:AAL) declined 6.2% to $10.45 in sympathy with Delta, which fell after reporting mixed quarterly earnings.
    • United Airlines Holdings, Inc. (NASDAQ:UAL) fell 5.5% to $44.58 in sympathy with Delta, which fell after reporting mixed quarterly earnings.
    • Celestica Inc. (NYSE:CLS) fell 5.4% to $58.18. Celestica is expected to release second quarter financial results on Wednesday, July 24.

    Now Read This:

    • Jim Cramer Says ‘Don’t Panic’ About Cava, Calls This Industrial Company ‘Terrific‘
    Get the next $AAL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAL
    $ASNS
    $ASTH
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    ConAgra Brands Inc.
    $CAG
    3/12/2026$15.00Equal Weight → Underweight
    Wells Fargo
    uniQure N.V.
    $QURE
    3/11/2026$35.00Neutral → Outperform
    Mizuho
    Strategy Inc
    $MSTR
    3/10/2026$175.00Buy
    B. Riley Securities
    uniQure N.V.
    $QURE
    3/9/2026$60.00Equal Weight → Overweight
    Wells Fargo
    uniQure N.V.
    $QURE
    3/9/2026$35.00Sector Perform → Outperform
    RBC Capital Mkts
    American Airlines Group Inc.
    $AAL
    3/5/2026$12.50Buy → Neutral
    Rothschild & Co Redburn
    uniQure N.V.
    $QURE
    3/3/2026$15.00Overweight → Equal Weight
    Wells Fargo
    uniQure N.V.
    $QURE
    3/3/2026$12.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Perez De La Mesa Manuel J bought $1,025,000 worth of shares (5,000 units at $205.00) (SEC Form 4)

    4 - POOL CORP (0000945841) (Issuer)

    3/17/26 4:06:43 PM ET
    $POOL
    Industrial Specialties
    Consumer Discretionary

    Director Taslitz Steven bought $223,500 worth of shares (300,000 units at $0.74), increasing direct ownership by 33% to 601,184 units (SEC Form 4)

    4 - BRC Inc. (0001891101) (Issuer)

    3/9/26 5:08:04 PM ET
    $BRCC
    Beverages (Production/Distribution)
    Consumer Staples

    Director Perez De La Mesa Manuel J bought $1,090,000 worth of shares (5,000 units at $218.00) (SEC Form 4)

    4 - POOL CORP (0000945841) (Issuer)

    3/4/26 4:08:55 PM ET
    $POOL
    Industrial Specialties
    Consumer Discretionary

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tang Yingzhi

    3 - Boqii Holding Ltd (0001815021) (Issuer)

    3/18/26 9:26:00 PM ET
    $BQ
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Jacob Gary S

    3 - OKYO Pharma Ltd (0001849296) (Issuer)

    3/18/26 8:37:54 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Cerrone Gabriele M

    3 - OKYO Pharma Ltd (0001849296) (Issuer)

    3/18/26 8:35:59 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Delta Air Lines Announces Webcast of March Quarter 2026 Financial Results

    ATLANTA, March 19, 2026 /PRNewswire/ -- Delta Air Lines (NYSE:DAL) will hold a live conference call and webcast to discuss its March quarter 2026 financial results at 10 a.m. ET, Wednesday, April 8, 2026. A live webcast of this event will be available at ir.delta.com and an online replay will be available shortly after the webcast is complete.About Delta Air LinesNo one better connects the worldThrough exceptional service and the power of innovation, Delta Air Lines (NYSE:DAL) never stops looking for ways to make every trip feel tailored to every customer.    There are 100,000 D

    3/19/26 11:00:00 AM ET
    $DAL
    Air Freight/Delivery Services
    Consumer Discretionary

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAL
    $ASNS
    $ASTH
    $BDRX
    SEC Filings

    View All

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:19:24 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:17:11 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:14:01 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Conagra downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Conagra from Equal Weight to Underweight and set a new price target of $15.00

    3/12/26 8:46:53 AM ET
    $CAG
    Packaged Foods
    Consumer Staples

    uniQure upgraded by Mizuho with a new price target

    Mizuho upgraded uniQure from Neutral to Outperform and set a new price target of $35.00

    3/11/26 8:30:07 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Strategy Inc with a new price target

    B. Riley Securities initiated coverage of Strategy Inc with a rating of Buy and set a new price target of $175.00

    3/10/26 8:42:16 AM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 9:58:25 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Tickets on Sale Today for United's First Boeing 787-9 Dreamliner with Elevated Interior Flights

    Travelers can book seats later today on the airline's most premium aircraft yet, the Boeing 787-9 Dreamliner with Elevated interior featuring the first United Polaris Studio℠ suites, roomier seats, larger seatback screens and Bluetooth connectivity at every seat in every cabinThe inaugural international flight, UA1, is scheduled for April 22 from San Francisco to Singapore; tickets will be for sale later today on United.com and the United appCHICAGO, March 19, 2026 /PRNewswire/ -- Starting today, travelers can book seats on United's most premium international aircraft yet – the 787-9 Dreamliner with the United Elevated interior. Unveiled last May, this new aircraft has been redesigned from n

    3/19/26 8:00:00 AM ET
    $UAL
    Air Freight/Delivery Services
    Consumer Discretionary

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    United and Chef's Table Bring Together World-Renowned Chefs to Create New, Exclusive Inflight Meals

    Regionally inspired dishes representing popular destinations such as Chicago, Los Angeles, London, and Tokyo, to be created by culinary legends like Nancy Silverton, Fariyal Abdullahi, Manu Buffara and moreNew meals expected to launch in Polaris international business class on August 1CHICAGO, March 12, 2026 /PRNewswire/ -- United is teaming up with Chef's Table, the brand behind the award-winning Netflix series, to introduce 10 new, exclusive meal experiences to its United Polaris® international business class menu. The airline has enlisted 11 world-renowned chefs from four continents – representing United's seven U.S. hub cities and key international gateways in London, Tokyo and São Paulo

    3/12/26 8:00:00 AM ET
    $UAL
    Air Freight/Delivery Services
    Consumer Discretionary

    $AAL
    $ASNS
    $ASTH
    $BDRX
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Delta Air Lines Announces Webcast of March Quarter 2026 Financial Results

    ATLANTA, March 19, 2026 /PRNewswire/ -- Delta Air Lines (NYSE:DAL) will hold a live conference call and webcast to discuss its March quarter 2026 financial results at 10 a.m. ET, Wednesday, April 8, 2026. A live webcast of this event will be available at ir.delta.com and an online replay will be available shortly after the webcast is complete.About Delta Air LinesNo one better connects the worldThrough exceptional service and the power of innovation, Delta Air Lines (NYSE:DAL) never stops looking for ways to make every trip feel tailored to every customer.    There are 100,000 D

    3/19/26 11:00:00 AM ET
    $DAL
    Air Freight/Delivery Services
    Consumer Discretionary

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care